



SciTech Development, LLC

For Immediate Release

SciTech to Present at 2020 MedInvest Virtual Infectious Diseases and Immunology Conference

(GROSSE POINTE FARMS, MI) June 10, 2020 – SciTech Development announced that it will deliver a corporate presentation and meet with investors at the 2020 MedInvest Virtual Infectious Diseases and Immunology Conference, June 15 &16, 2020.

Earle Holsapple (SciTech President) and Dr. Brian Leyland-Jones (SciTech Chief Medical Officer) will be presenting the company's lead oncology drug ST-001 nanoFenretinide which is being leveraged as a COVID-19 therapeutic. The company's virtual presentation is scheduled for

Date: Monday, June 15, 2020

Time: 1:30 PM (ET)



Qualified investors can register to attend the virtual conference for free. Visit <https://www.medinvestconferences.com/> for additional information or call Earle Holsapple at (313) 938-5517 to schedule 1-on-1 virtual meetings which will continue to be held June 15-17, 2020.

ST-001 nanoFenretinide may offer additional support in the battle against the COVID-19 pandemic. The drug recently demonstrated antiviral activity against SARS-CoV-2; and, published data supports the use of the active agent fenretinide as an anti-inflammation agent. SciTech is seeking immediate funding to enter a COVID-19 Phase 1 clinical trial that leverages the company's existing FDA approved IND for an oncology indication.



About SciTech Development

SciTech Development, LLC, is a clinical stage specialty pharmaceutical company focused on novel, advanced drug delivery mechanisms for use with cancer therapeutics. SciTech's patented

and differentiated drug delivery system, SDV, is a proprietary intravenous, phospholipid-based, nanoparticle product. SDV enables drug assets, such as fenretinide, that are water insoluble, to be distributed through the circulatory system in sufficient quantities and doses to reach the target cells and produce a therapeutic effect while maintaining low toxicity levels. In its primary capacity as an oncology drug development company, SciTech's Investigational New Drug Application (IND) for ST-001 treatment of T-cell non-Hodgkin's lymphoma (NHL) was accepted last December. Additionally, the FDA has granted Orphan Drug Designation status for ST-001 in the treatment of two types of NHL: peripheral T-cell lymphoma and cutaneous T-cell lymphoma. Solid preclinical and clinical data makes the case for the use of fenretinide in the treatment of additional blood disorders and solid tumors such as small cell lung, breast, pancreatic, neuroblastoma and other cancers. SciTech Development is headquartered in the Metropolitan Detroit Michigan Area with laboratories at the Sinai Hospital BioIncubator in Baltimore Maryland. Information regarding SciTech's nano formulation technology and ST-001 nanoFenretinide drug product is available from SciTech Development, LLC by calling (313) 938-5517 or at <https://www.scitechdevelopment.com/>.

Forward-Looking Information

This press release and linked information contains forward-looking statements, including information about management's view of SciTech Development LLC ("the Company"), future expectations, plans and prospects. In particular, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this release and linked information other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this press release and linked information are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by SciTech Development LLC.

Connect & Follow Us



#####